Poster

2022 World Muscle Society Congress

A Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA Study Design

AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD

Durable AOC Mediated Exon 44 Skipping In Non-Human Primate Muscle Tissue And Dystrophin Protein Restoration In DMD Patient Derived Skeletal Muscle Cells

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM) Pre- and Post-Diagnosis: A Real-World Data Analysis

Understanding the Patients’ Journey Pre- and Post-Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): A Real-World Retrospective Data Analysis

Poster

2022 74th AAN Annual Meeting

Study Design of AOC 1001-CS1, a Phase 1/2 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Patients with Myotonic Dystrophy Type 1 (DM1) (MARINA™) 

Antibody-Oligonucleotide Conjugates (AOCs) Demonstrate Potent and Durable Exon Skipping and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy

Prevalence of healthcare conditions and services used by patients with myotonic dystrophy (DM1 and DM2) prior to diagnosis; a real-world data analysis

Understanding the patients’ journey to the diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a real-world retrospective data analysis

DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOC™) for the Treatment of FSHD

Poster

2022 MDA Clinical and Scientific Conference

DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOCTM) for the Treatment of FSHD

A Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1 (DM1): MARINA Study Design

Understanding the patients’ journey pre- and post-diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a real-world retrospective data analysis 

Prevalence of healthcare conditions and services used by patients with myotonic dystrophy pre-and post-diagnosis, a real-world data analysis 

Management

Kathleen Gallagher

Kathleen Gallagher joined Avidity Biosciences in April 2021 and serves as Chief Program Officer. She previously held the roles of Senior Vice President and Global Program Head, Myotonic Dystrophy Type 1 (DM1) and Senior Vice President of Corporate Communications and Investor Relations. Ms. Gallagher brings more than 20 years of experience in the biopharmaceutical industry leading communications and investor relations in preclinical to commercial stage companies. Prior to joining Avidity, she was Vice President, Investor Relations and Corporate Communications at Akcea Therapeutics (acquired by Ionis Pharmaceuticals), where her communications strategy and relationship building expertise were essential through the development and commercial launches of rare disease therapies Tegsedi® and Waylivra®. Previously, she held roles of increasing responsibility during her 13-year tenure at Merrimack Pharmaceuticals, where she provided leadership and direction through multiple financing rounds including an IPO and through the launch of the pancreatic cancer therapy ONIVYDE®. Ms. Gallagher earned her B.S. degree in English from Boston University.

BOD

Sarah Boyce

Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity has been marked by transformative leadership, starting with the company’s successful Series C funding round and IPO. She continues to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three therapies into clinical development and the expansion of the broad utility of the company’s proprietary RNA technology. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the board of directors at OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. Sarah holds a BSc (Hons) degree in microbiology from the University of Manchester, England.